GoAI
Get started
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc.

LCTX

AMEXHealthcareBiotechnology

Open in GoAI

Previous close

$1.08

$0.00 · 0.00%

Aug 21, 4:00 PM ET

Pre-market

$1.0898

+$0.0098 · +0.91%

Aug 24, 7:21 AM ET

LCTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

28

Weakening

Sentiment

53

Mixed

Risk resilience

39

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Brian Culley
Listed since
Mar 5, 1992
Employees
75

Market position

Day range

Current $1.08

52-week range

Current $1.08

Open
$1.075
Previous close
$1.08
Volume
709.51K
0.52× average
Average volume
1.36M
Average daily volume
Market cap
269.24M USD
Beta
1.55
Market reference 1
50-day average
$1.1764
-8.19% below average
200-day average
$1.5011
-28.05% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
345.92M USD
P/E (TTM)
-7.7×
P/B (TTM)
4.42×
P/S (TTM)
20.58×
EV / EBITDA
-5.09×
Earnings yield
-16.53%
Free cash flow yield
-5.06%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
96.59%
Operating margin
-205.23%
Net margin
-246.58%
Return on equity
-142.61%
Return on assets
-56.43%
Return on invested capital
-19.75%

Financial health

Debt / equity
0.04×
Current ratio
5.2×
Altman Z-score
-3.25
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends232%-311%-855%-1399%Gross margin, FY2021: 63.40%Gross margin, FY2022: 95.05%Gross margin, FY2023: 92.50%Gross margin, FY2024: 96.48%Gross margin, FY2025: 94.19%Operating margin, FY2021: -1263.12%Operating margin, FY2022: -153.17%Operating margin, FY2023: -276.50%Operating margin, FY2024: -226.11%Operating margin, FY2025: -149.62%Net margin, FY2021: -1104.18%Net margin, FY2022: -178.69%Net margin, FY2023: -240.20%Net margin, FY2024: -195.90%Net margin, FY2025: -436.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.40%. Gross margin FY2022 95.05%. Gross margin FY2023 92.50%. Gross margin FY2024 96.48%. Gross margin FY2025 94.19%. Operating margin FY2021 -1263.12%. Operating margin FY2022 -153.17%. Operating margin FY2023 -276.50%. Operating margin FY2024 -226.11%. Operating margin FY2025 -149.62%. Net margin FY2021 -1104.18%. Net margin FY2022 -178.69%. Net margin FY2023 -240.20%. Net margin FY2024 -195.90%. Net margin FY2025 -436.47%.

Income trends

Revenue

14.56M USD+53.24%

Operating income

−21.78M USD-1.40%

Net income

−63.53M USD-241.41%
Income trends across reported periods22.53M USD−8.77M USD−40.06M USD−71.36M USDRevenue, FY2021: 3.9M USDRevenue, FY2022: 14.7M USDRevenue, FY2023: 8.95M USDRevenue, FY2024: 9.5M USDRevenue, FY2025: 14.56M USDOperating income, FY2021: −49.21M USDOperating income, FY2022: −22.52M USDOperating income, FY2023: −24.73M USDOperating income, FY2024: −21.48M USDOperating income, FY2025: −21.78M USDNet income, FY2021: −43.02M USDNet income, FY2022: −26.27M USDNet income, FY2023: −21.49M USDNet income, FY2024: −18.61M USDNet income, FY2025: −63.53M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.9M USD. Revenue FY2022 14.7M USD. Revenue FY2023 8.95M USD. Revenue FY2024 9.5M USD. Revenue FY2025 14.56M USD. Operating income FY2021 −49.21M USD. Operating income FY2022 −22.52M USD. Operating income FY2023 −24.73M USD. Operating income FY2024 −21.48M USD. Operating income FY2025 −21.78M USD. Net income FY2021 −43.02M USD. Net income FY2022 −26.27M USD. Net income FY2023 −21.49M USD. Net income FY2024 −18.61M USD. Net income FY2025 −63.53M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue14.56M USD9.5M USD8.95M USD14.7M USD3.9M USD
Cost of goods sold845K USD334K USD671K USD728K USD1.43M USD
Gross profit13.71M USD9.17M USD8.27M USD13.98M USD2.47M USD
Research and development17.73M USD12.47M USD15.71M USD13.99M USD33.91M USD
Selling, general, and administrative18.46M USD18.17M USD17.3M USD22.51M USD18.21M USD
Operating expenses35.49M USD30.64M USD33.01M USD36.5M USD51.68M USD
Interest income1.69M USD1.72M USD1.63M USD829K USD2K USD
Depreciation and amortization699K USD609K USD692K USD727K USD873K USD
Operating income−21.78M USD−21.48M USD−24.73M USD−22.52M USD−49.21M USD
Net income−63.53M USD−18.61M USD−21.49M USD−26.27M USD−43.02M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-38.14%
11 comparable reports
Latest EPS result
-0.03
Estimate -0.03 · Miss by 5.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.04-0.03-0.1-0.17Q1 '25BeatQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual -0.01, estimate -0.04, surprise +75.00%, Beat. Q2 2025, reported May 13, 2025: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q3 2025, reported Aug 12, 2025: actual -0.01, estimate -0.02, surprise +50.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.13, estimate -0.02, surprise -550.00%, Miss. Q1 2026, reported Mar 5, 2026: actual 0.004, estimate -0.043, surprise +109.23%, Beat. Q2 2026, reported May 12, 2026: actual -0.03, estimate -0.02, surprise -50.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.03, estimate -0.028, surprise -5.89%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.03, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.04M5M2.95M908.65KQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 10, 2025: actual 2.9M USD, estimate 1.62M USD, surprise +78.88%, Beat. Q2 2025, reported May 13, 2025: actual 1.5M USD, estimate 1.72M USD, surprise -12.89%, Miss. Q3 2025, reported Aug 12, 2025: actual 2.77M USD, estimate 1.47M USD, surprise +88.57%, Beat. Q4 2025, reported Nov 6, 2025: actual 3.68M USD, estimate 1.96M USD, surprise +87.85%, Beat. Q1 2026, reported Mar 5, 2026: actual 6.6M USD, estimate 1.96M USD, surprise +236.81%, Beat. Q2 2026, reported May 12, 2026: actual 1.73M USD, estimate 3.6M USD, surprise -52.10%, Miss. Q3 2026, reported Aug 6, 2026: actual 1.07M USD, estimate 1.84M USD, surprise -41.97%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.28M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy5100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
Maxim GroupmaintainBuy
Cantor FitzgeraldmaintainOverweight

LCTX news

marketbeat.com

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and…

Read source
seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.

Read source
businesswire.com

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.

Read source
marketbeat.com

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential…

Read source
seekingalpha.com

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend Dec 15, 2003

$0.08

Irregular

LCTX peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

—

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

—

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

—

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

—

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

—

Armata Pharmaceuticals, Inc. logo

ARMP

Armata Pharmaceuticals, Inc.

$5.10

—

ETFs holding LCTX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.38M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
4.42M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.21M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.87M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.5M
Weight
0.01%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.12M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
689.94K
Weight
0.05%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF logoGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC
Market value
251.1K
Weight
0.02%
AUM
1.09B USD
Expense ratio
0.20%
Price / 1D
$91.32+0.82%

Continue in GoAI

Research LCTX

research.disclaimer